Kairos Pharma Ltd. (NYSE American: KAPA) has received a Department of Defense grant to further its lung cancer biomarker research, highlighting the company's strategic focus on developing innovative cancer treatments that address drug resistance and immune suppression.
The company is currently advancing two critical clinical trials for its lead candidate ENV105, targeting prostate and EGFR-dependent non-small cell lung cancers. Expected safety and interim efficacy results in the second quarter of 2025 could represent a significant breakthrough in cancer treatment approaches.
ENV105, an antibody targeting CD105, aims to overcome a critical challenge in cancer therapy: the protein's role in treatment resistance. By targeting CD105, the drug seeks to restore the effectiveness of standard therapies across multiple cancer types, potentially transforming how resistant cancers are treated.
In addition to ENV105, Kairos is developing KROS101, an immune response modulator, and has recently presented data at key oncology conferences. The company's research is supported by non-dilutive government grants and has attracted analyst coverage from prominent firms like EF Hutton and HC Wainwright.
With a robust intellectual property portfolio extending into the 2030s, Kairos Pharma demonstrates a long-term commitment to advancing oncological research. The Department of Defense grant underscores the potential significance of the company's approach in addressing critical unmet medical needs in cancer treatment.
